Zobrazeno 1 - 10
of 203
pro vyhledávání: '"S A Tjulandin"'
Autor:
E. M. Polyanskaya, M. Yu. Fedyanin, U. A. Boyarskikh, A. A. Kechin, E. A. Moroz, A. N. Polyakov, N. E. Kudashkin, D. V. Podluzhniy, E. A. Khrapov, I. P. Oskorobin, D. V. Shamovskaya, V. A. Aliev, Z. Z. Mamedli, A. A. Tryakin, M. L. Filipenko, S. A. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 12, Iss 1, Pp 27-34 (2022)
Background. Circulating tumor DnA (ctDnA) may act as a potential biomarker for predicting disease progression in patients with colorectal cancer (CRC), which are radically cured or receiving chemotherapy.Objective: to evaluate the sensitivity of the
Externí odkaz:
https://doaj.org/article/99f589873ede4c1ba404acaf9753fe7a
Autor:
M. Yu. Fedyanin, К M. Ehlsnukaeva, I. A. Demidova, D. L. Stroyakovskiy, Yu. A. Shelygin, А. S. Tsukanov, М. V. Panina, V. Р. Shubin, F. V. Moiseenko, E. Yu. Karpenko, L. V. Bolotina, A. V. Kudryavtseva, М. L. Filipenko, I. P. Oskorbin, L. Yu. Vladimirova, N. N. Timoshkina, О. I. Kit, А. М. Stroganova, S. L. Dranko, А. I. Senderovich, А. А. Tryakin, S. А. Tjulandin
Publikováno v:
Медицинский совет, Vol 0, Iss 4S, Pp 52-63 (2021)
Introduction. mBRAF mCRC has the aggressive phenotype. The incidence of such mutation in Europe and the USA is around 8–14%, in Asian countries – 4–8%. The purpose of this population-based study was to determine the incidence and identifying pr
Externí odkaz:
https://doaj.org/article/21aec854212c4d9b9c6cc69e2d4c8fab
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, M. A. Lyadova, V. N. Vorobyeva, V. V. Petkau, A. V. Fateeva, E. S. Kuzmina, O. Yu. Novikova, V. A. Chubenko, N. Kh. Abduloeva, A. A. Kudryavtsev, E. O. Ignatova, R. R. Shakirov, O. A. Pardabekova, L. V. Kindyalova, S. P. Pelikh, O. A. Gladkov, S. A. Tjulandin, A. A. Tryakin
Publikováno v:
Тазовая хирургия и онкология, Vol 11, Iss 1, Pp 11-20 (2021)
Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods. This re
Externí odkaz:
https://doaj.org/article/ab81d2b18b6d483387d0ba158a69a3b1
Autor:
M. Yu. Fedyanin, E. M. Polyanskaya, H. H.-M. Elsnukaeva, A. A. Tryakin, I. A. Pokataev, A. A. Bulanov, S. A. Tjulandin
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 125-132 (2020)
Introduction. Based on the subgroup analysis of the TRIBE study FOLFOXIRI with bevacizumab is the recommended option for patients (pts) with mBRAF metastatic colorectal cancer (mCRC) in the 1st line. However, subgroup analysis of other studies showed
Externí odkaz:
https://doaj.org/article/ee57e07abaa94e0ca701173d11ac940a
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 47-52 (2020)
Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines,
Externí odkaz:
https://doaj.org/article/7960a21c1a0a4a80b8f80fc55c3111e3
Autor:
M. Yu. Fedyanin, E. M. Polyanskaya, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh.-Kh. M. Elsnukaeva, A. N. Polyakov, I. V. Sagaydak, V. D. Podluzhniy, V. A. Aliev, S. S. Gordeev, D. V. Kuzmichev, Z. Z. Mamedli, S. A. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 4, Pp 21-31 (2019)
Objective: to assess the frequency of liver resections in patients with metastatic colon cancer and isolated non-resectable liver metastases receiving FOLFOXIRI. Materials and methods. In this single-center non-randomized prospective study, we assess
Externí odkaz:
https://doaj.org/article/96030a321071492db3b25dc0e696bf00
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, E. A. Kalabanova, Е. G. Panina, A. I. Arzamastseva, E. G. Rybakov, L. V. Bolotina, T. V. Ustinova, А. А. Kachmazov, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh. Kh.-M. Elsnukaeva, D. V. Podluzhniy, S. A. Tjulandin, O. I. Kit
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 1, Pp 65-72 (2019)
Objective: to analyze the frequency of metastasectomy in general population of patients with RAS wild-type metastatic colorectal cancer who received chemotherapy and anti-EGFR monoclonal antibodiesMaterials and methods. This prospective, non-randomiz
Externí odkaz:
https://doaj.org/article/7ebf77bf1fc84cfd9d615caaea1ff937
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, L. V. Bolotina, F. V. Moiseenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseenko, А. А. Meshcheryakov, E. V. Artamonova, I. A. Pokataev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, A. A. Tryakin, S. A. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 2, Pp 29-37 (2019)
Objective: to identify factors associated with efficacy of an aflibercept-chemotherapy combination in patients with metastatic colon cancer.Materials and methods. This retrospective multicenter study was conducted in 20 clinics from 15 regions of the
Externí odkaz:
https://doaj.org/article/743bdd161bd0481991ada713bfba7dbc
Publikováno v:
Тазовая хирургия и онкология, Vol 8, Iss 4, Pp 11-29 (2018)
Today there is no unified colorectal cancer screening program. The whole number of different screening tests exists, which significantly differs from each other as a methodology and cost, as the object of study. The purpose of this review is the anal
Externí odkaz:
https://doaj.org/article/249d31ed4c084402bdc39f7a05d26bc3
Autor:
M. Yu. Fedyanin, Kh. Kh.-M. Elsnukaeva, V. A. Aliev, T. S. Ayrapetyan, A. V. Polyakov, E. V. Moroz, V. A. Uymanov, U. A. Boyarskikh, A. A. Kechin, M. L. Filipenko, S. А. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 8, Iss 3, Pp 11-16 (2018)
Colon cancer is the 3rd most common malignant neoplasm and the 4th leading cause of mortality from them. The majority of patients are diagnosed at stages II–IV, which indicates the need for markers that can predict disease progression, especially a
Externí odkaz:
https://doaj.org/article/ab372d1968ee42b2bc22fe2a90273fb0